Vir Biotechnology (VIR) Cash & Equivalents (2018 - 2026)

Vir Biotechnology has disclosed Cash & Equivalents across 9 years of filings, most recently posting $274.2 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $274.2 million, changed 0.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $274.2 million (changed 0.22% YoY), and the FY2025 annual result was $232.2 million, up 159.76% from the prior year.
• Cash & Equivalents came in at $274.2 million for Q1 2026 at Vir Biotechnology, up from $232.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $963.7 million in Q3 2022 to a low of $11.0 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $232.2 million (2025), against an average of $307.1 million.
• Across the five-year window, Cash & Equivalents surged 9774.69% in 2022 and sank 98.65% in 2023, its largest moves.
• Vir Biotechnology's Cash & Equivalents stood at $848.6 million in 2022, then tumbled by 71.53% to $241.6 million in 2023, then sank by 63.0% to $89.4 million in 2024, then soared by 159.76% to $232.2 million in 2025, then gained by 18.08% to $274.2 million in 2026.
• The last three Cash & Equivalents figures came in at $274.2 million (Q1 2026), $232.2 million (Q4 2025), and $170.1 million (Q3 2025), per Business Quant data.